Disitamab Vedotin Injection

DRUG4 trials

Sponsors

RemeGen Co., Ltd., Sun Yat-sen University

Conditions

Bladder CancerBreast CancerCastration-resistant Prostate CancerGastric CancerGastroesophageal Junction AdenocarcinomaMuscle-invasive Bladder Cancer

Phase 1

Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Not yet recruitingNCT06957561

Sun Yat-sen UniversityBladder Cancer, Muscle-invasive Bladder Cancer

Start: 2025-04-30End: 2029-05-01Target: 30Updated: 2025-05-04

Phase 2

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

RecruitingNCT06178159

RemeGen Co., Ltd.Breast Cancer

Start: 2023-11-28End: 2026-12-31Target: 40Updated: 2025-10-01

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

RecruitingNCT06221748

RemeGen Co., Ltd.Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

Start: 2024-02-22End: 2027-12-31Target: 90Updated: 2024-04-03

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

RecruitingNCT06227156

RemeGen Co., Ltd.Castration-resistant Prostate Cancer

Start: 2024-04-08End: 2026-06-30Target: 40Updated: 2024-05-23

Related Papers

Safety and efficacy of neoadjuvant disitamab vedotin in combination with pertuzumab with or without toripalimab for HER2-positive breast cancer: An open-label phase II trial.

Journal of Clinical Oncology2025-05-28